三种射频技术对比的随机对照试验:3-RF试验短期结果
3-RF试验是首个比较三种商用射频消融技术的随机双盲对照试验,纳入182/302例大隐静脉功能不全患者,比较Venefit、RFITT和EVRF。主要终点为6个月时大隐静脉闭合情况。结果显示Venefit和RFITT的完全闭合率显著优于EVRF(100%和98% vs 79%,p < .001),但12个月时临床结局无显著差异。
要点
- 6个月完全闭合率Venefit 100%、RFITT 98%显著优于EVRF 79%(p < .001)。
- RFITT平均治疗时间显著快于Venefit和EVRF(p < .0001)。
- 12个月时各组临床结局(QoL、AVVQ)无显著差异。
核心结论
- 与Venefit和RFITT相比,EVRF在6个月时与显著的主干消融失败相关,但12个月时临床结局无显著差异。
研究设计与样本
- 前瞻性双盲随机对照试验,纳入182/302例大隐静脉功能不全患者,随机分配至Venefit、RFITT和EVRF三组。
- 主要终点为6个月时大隐静脉闭合情况(完全/部分/失败),次要终点包括消融时间、并发症、疼痛评分、镇痛需求和生活质量至12个月。
主要发现
- 6个月时完全闭合率Venefit 100%、RFITT 98%显著优于EVRF 79%(p < .001)。
- RFITT平均治疗时间显著快于Venefit和EVRF(p < .0001)。
- EQ5D视觉模拟评分各组各时间点无差异;仅2周时EVRF组疼痛/不适域报告无问题者显著少于Venefit和RFITT组,6和12个月时差异消失。
- AVVQ各组6和12个月较治疗前改善,组间无显著差异。
关键数值与推荐
- 6个月完全闭合率:Venefit 100%,RFITT 98%,EVRF 79%(p < .001)。
- 平均治疗时间RFITT显著快于Venefit和EVRF(p < .0001)。
临床怎么用
- 选择射频消融设备时,Venefit和RFITT在6个月主干闭合方面优于EVRF,但12个月临床结局相似。
- RFITT治疗时间更短,可能提高手术效率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To date there has been no comparison of outcomes of endovenous radiofrequency (RF) devices. The 3-RF trial is the first randomised controlled trial of three commercially available RF ablation technologies. METHODS: Patients were recruited [182/302 patients with great saphenous vein (GSV) incompetence] into a prospective double blind randomised trial of Venefit, radiofrequency induced thermal therapy (RFITT), and endovenous radiofrequency (EVRF). The primary outcome measure was GSV closure (total/partial/failed) at six months. Secondary outcome measures included ablation times, complications, pain scores, analgesia requirements, and quality of life (QoL) scores to 12 months. RESULTS: Patients treated [180: Venefit (57), RFITT (64), EVRF (59)] were matched for age, sex, and vein characteristics. At six months, complete GSV closure was significantly better after Venefit and RFITT treatment (100% and 98%, respectively) compared with EVRF treatment (79%, p < .001). Mean treatment time was significantly faster for RFITT than for Venefit and EVRF (p < .0001). Euroqol 5D (EQ5D) visual analogue score (VAS) did not differ between groups at any time point. The only difference between groups in EQ5D domain scores was for the pain/discomfort domain at two weeks when significantly fewer EVRF patients reported no problems compared with Venefit and RFITT. This difference had disappeared at six and 12 months. The Aberdeen Varicose Vein Questionnaire (AVVQ) improved for all groups at six and 12 months compared with pre-treatment levels; however, there was no significant difference between groups. CONCLUSION: Compared with Venefit and RFITT, EVRF was associated with significant failure of truncal ablation at six months; however, clinical outcomes did not differ significantly at 12 months. clinicaltrials.gov identifier: NCT02441881, NHS Health Research Authority (Hampstead Research Ethics Committee) number: 14/LO/1232.
引用
- Nyamekye IK, Dattani N, Hayes W, et al. A Randomised Controlled Trial Comparing Three Different Radiofrequency Technologies: Short-Term Results of the 3-RF Trial. Eur J Vasc Endovasc Surg. 2019. PMID: 31351832. doi:10.1016/j.ejvs.2019.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。